At a glance
- Originator Servier
- Class Antiplatelets; Vasodilators
- Mechanism of Action Thromboxane A2 synthase inhibitors; Thromboxane receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Thrombosis
Most Recent Events
- 04 Apr 2000 New profile
- 04 Apr 2000 Preclinical development for Atherosclerosis in France (Unknown route)
- 04 Apr 2000 Preclinical development for Thrombosis in France (Unknown route)